WEKO3
アイテム
{"_buckets": {"deposit": "8f8939fc-9a92-48c5-9e57-3ba829e0d9e9"}, "_deposit": {"created_by": 1, "id": "85155", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "85155"}, "status": "published"}, "_oai": {"id": "oai:repo.qst.go.jp:00085155", "sets": ["1"]}, "author_link": ["1026505", "1026510", "1026509", "1026513", "1026506", "1026515", "1026507", "1026508", "1026511", "1026514", "1026516", "1026512"], "item_8_biblio_info_7": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2021-12", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "2", "bibliographicPageEnd": "732", "bibliographicPageStart": "721", "bibliographicVolumeNumber": "113", "bibliographic_titles": [{"bibliographic_title": "Cancer Science"}]}]}, "item_8_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Synovial sarcomas are rare tumors arising in adolescents and young adults. The prognosis for advanced disease is poor, with an overall survival of 12-18 months. Frizzled homolog 10 (FZD10) is overexpressed in most synovial sarcomas, making it a promising therapeutic target. The results of a phase 1 trial of β-radioimmunotherapy (RIT) with the 90Y-labeled anti-FZD10 antibody OTSA101 revealed a need for improved efficacy. The present study evaluated the potential of α-RIT with OTSA101 labeled with the α-emitter 225Ac. Competitive inhibition and cell binding assays showed that specific binding of 225Ac-labeled OTSA101 to SYO-1 synovial sarcoma cells was comparable to that of the imaging agent 111In-labeled OTSA101. Biodistribution studies showed high uptake in SYO-1 tumors and low uptake in normal organs, except for blood. Dosimetric studies showed that the biologically effective dose (BED) of 225Ac-labeled OTSA101 for tumors was 7.8 Bd higher than that of 90Y-labeled OTSA101. 90Y- and 225Ac-labeled OTSA101 decreased tumor volume and prolonged survival. 225Ac-labeled OTSA101 achieved a complete response in 60% of mice, and no recurrence was observed. 225Ac-labeled OTSA101 induced a larger amount of necrosis and apoptosis than 90Y-labeled OTSA101, although the cell proliferation decrease was comparable. The BED for normal organs and tissues was tolerable; no treatment-related mortality or obvious toxicity, except for temporary body weight loss, was observed. 225Ac-labeled OTSA101 provided a high BED for tumors and achieved a 60% complete response in the synovial sarcoma mouse model SYO-1. RIT with 225Ac-labeled OTSA101 is a promising therapeutic option for synovial sarcoma.", "subitem_description_type": "Abstract"}]}, "item_8_publisher_8": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Wiley Online Library"}]}, "item_8_relation_13": {"attribute_name": "PubMed番号", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "34935247", "subitem_relation_type_select": "PMID"}}]}, "item_8_relation_14": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1111/cas.15235", "subitem_relation_type_select": "DOI"}}]}, "item_8_relation_17": {"attribute_name": "関連サイト", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "https://onlinelibrary.wiley.com/doi/full/10.1111/cas.15235", "subitem_relation_type_select": "URI"}}]}, "item_8_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1347-9032", "subitem_source_identifier_type": "ISSN"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "metadata only access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_14cb"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Hitomi, Sudo"}], "nameIdentifiers": [{"nameIdentifier": "1026505", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Atsushi, Tsuji"}], "nameIdentifiers": [{"nameIdentifier": "1026506", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Aya, Sugyo"}], "nameIdentifiers": [{"nameIdentifier": "1026507", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yosuke , Harada"}], "nameIdentifiers": [{"nameIdentifier": "1026508", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Satoshi , Nagayama"}], "nameIdentifiers": [{"nameIdentifier": "1026509", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Toyomasa , Katagiri"}], "nameIdentifiers": [{"nameIdentifier": "1026510", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yusuke , Nakamura"}], "nameIdentifiers": [{"nameIdentifier": "1026511", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tatsuya, Higashi"}], "nameIdentifiers": [{"nameIdentifier": "1026512", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hitomi, Sudo", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1026513", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Atsushi, Tsuji", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1026514", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Aya, Sugyo", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1026515", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tatsuya, Higashi", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1026516", "nameIdentifierScheme": "WEKO"}]}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "FZD10-targeted α-radioimmunotherapy with 225Ac-labeled OTSA101 achieves complete remission in a synovial sarcoma model", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "FZD10-targeted α-radioimmunotherapy with 225Ac-labeled OTSA101 achieves complete remission in a synovial sarcoma model"}]}, "item_type_id": "8", "owner": "1", "path": ["1"], "permalink_uri": "https://repo.qst.go.jp/records/85155", "pubdate": {"attribute_name": "公開日", "attribute_value": "2021-12-22"}, "publish_date": "2021-12-22", "publish_status": "0", "recid": "85155", "relation": {}, "relation_version_is_last": true, "title": ["FZD10-targeted α-radioimmunotherapy with 225Ac-labeled OTSA101 achieves complete remission in a synovial sarcoma model"], "weko_shared_id": -1}
FZD10-targeted α-radioimmunotherapy with 225Ac-labeled OTSA101 achieves complete remission in a synovial sarcoma model
https://repo.qst.go.jp/records/85155
https://repo.qst.go.jp/records/85155619f0a00-9299-4ed2-97c9-47016b69887f
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2021-12-22 | |||||
タイトル | ||||||
タイトル | FZD10-targeted α-radioimmunotherapy with 225Ac-labeled OTSA101 achieves complete remission in a synovial sarcoma model | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
Hitomi, Sudo
× Hitomi, Sudo× Atsushi, Tsuji× Aya, Sugyo× Yosuke , Harada× Satoshi , Nagayama× Toyomasa , Katagiri× Yusuke , Nakamura× Tatsuya, Higashi× Hitomi, Sudo× Atsushi, Tsuji× Aya, Sugyo× Tatsuya, Higashi |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Synovial sarcomas are rare tumors arising in adolescents and young adults. The prognosis for advanced disease is poor, with an overall survival of 12-18 months. Frizzled homolog 10 (FZD10) is overexpressed in most synovial sarcomas, making it a promising therapeutic target. The results of a phase 1 trial of β-radioimmunotherapy (RIT) with the 90Y-labeled anti-FZD10 antibody OTSA101 revealed a need for improved efficacy. The present study evaluated the potential of α-RIT with OTSA101 labeled with the α-emitter 225Ac. Competitive inhibition and cell binding assays showed that specific binding of 225Ac-labeled OTSA101 to SYO-1 synovial sarcoma cells was comparable to that of the imaging agent 111In-labeled OTSA101. Biodistribution studies showed high uptake in SYO-1 tumors and low uptake in normal organs, except for blood. Dosimetric studies showed that the biologically effective dose (BED) of 225Ac-labeled OTSA101 for tumors was 7.8 Bd higher than that of 90Y-labeled OTSA101. 90Y- and 225Ac-labeled OTSA101 decreased tumor volume and prolonged survival. 225Ac-labeled OTSA101 achieved a complete response in 60% of mice, and no recurrence was observed. 225Ac-labeled OTSA101 induced a larger amount of necrosis and apoptosis than 90Y-labeled OTSA101, although the cell proliferation decrease was comparable. The BED for normal organs and tissues was tolerable; no treatment-related mortality or obvious toxicity, except for temporary body weight loss, was observed. 225Ac-labeled OTSA101 provided a high BED for tumors and achieved a 60% complete response in the synovial sarcoma mouse model SYO-1. RIT with 225Ac-labeled OTSA101 is a promising therapeutic option for synovial sarcoma. | |||||
書誌情報 |
Cancer Science 巻 113, 号 2, p. 721-732, 発行日 2021-12 |
|||||
出版者 | ||||||
出版者 | Wiley Online Library | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 1347-9032 | |||||
PubMed番号 | ||||||
識別子タイプ | PMID | |||||
関連識別子 | 34935247 | |||||
DOI | ||||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1111/cas.15235 | |||||
関連サイト | ||||||
識別子タイプ | URI | |||||
関連識別子 | https://onlinelibrary.wiley.com/doi/full/10.1111/cas.15235 |